US equities
|
SPCX
$168.81
▲+6.20%
NVDA
$237.48
▲+1.51%
MU
$1,065.33
▼-0.89%
TSLA
$380.79
▲+2.75%
MSFT
$524.76
▲+1.40%
SNDK
$1,714.33
▼-0.33%
INTC
$116.87
▼-2.06%
META
$744.34
▲+2.23%
SPCX
$168.81
▲+6.20%
NVDA
$237.48
▲+1.51%
MU
$1,065.33
▼-0.89%
TSLA
$380.79
▲+2.75%
MSFT
$524.76
▲+1.40%
SNDK
$1,714.33
▼-0.33%
INTC
$116.87
▼-2.06%
META
$744.34
▲+2.23%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
90.35
-2.48 (-2.67%)
Delayed Quote
Updated: 1:42 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
July 12, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
July 10, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells
↗
July 10, 2025
Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.
Via
Stocktwits
Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
↗
June 05, 2025
Via
Benzinga
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
↗
May 29, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 09, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
July 09, 2025
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise
↗
July 09, 2025
Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
July 09, 2025
Via
Benzinga
These stocks are moving in today's session
↗
July 09, 2025
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity
↗
July 09, 2025
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.
Via
Stocktwits
Topics
Government
Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity
↗
July 09, 2025
Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat obesity.
Via
Investor's Business Daily
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
↗
July 09, 2025
Via
Benzinga
Which stocks are gapping on Wednesday?
↗
July 09, 2025
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
July 09, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
↗
July 08, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
July 08, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
8 Analysts Have This To Say About Rhythm Pharmaceuticals
↗
June 26, 2025
Via
Benzinga
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
June 25, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) – A Strong Growth Candidate Meeting Minervini’s Criteria
↗
May 22, 2025
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors.
Via
Chartmill
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
May 14, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
↗
May 07, 2025
Via
Benzinga
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
May 07, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
May 06, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
April 23, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
↗
April 13, 2025
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.
Via
Benzinga
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
↗
April 08, 2025
Via
Benzinga
Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
April 08, 2025
Via
Benzinga
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish
↗
April 07, 2025
CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.
Via
Stocktwits
Topics
Government
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
